Synchronous occurrence of squamous-cell carcinoma “transformation” and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR -mutated lung adenocarcinoma

Highlights • The synchronous occurrence of SCC “transformation” and exon 20 S768I is described. • SCC transformation and exon 20 S768I is an unreported mechanism of resistance. • This situation is challenging for clinicians in the choice of a second line therapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-01, Vol.103, p.24-26
Hauptverfasser:	Longo, Lucia, Mengoli, Maria Cecilia, Bertolini, Federica, Bettelli, Stefania, Manfredini, Samantha, Rossi, Giulio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - complications Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - complications Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Disease Progression Drug Resistance, Neoplasm - genetics EGFR ErbB Receptors - genetics Exons Fatal Outcome Female Gefitinib Hematology, Oncology and Palliative Medicine Humans Lung cancer Lung Neoplasms - complications Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Quinazolines - administration & dosage Quinazolines - therapeutic use Squamous cell carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The synchronous occurrence of SCC “transformation” and exon 20 S768I is described. • SCC transformation and exon 20 S768I is an unreported mechanism of resistance. • This situation is challenging for clinicians in the choice of a second line therapy
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.11.012